) and intensity of staining (0-3+). A 5hmC score was calculated by multiplying the percentage and intensity scores (range 0-9), and a score of <3 was considered deficient for 5hmC. Results: Normal and cirrhotic liver parenchyma showed predominantly intact expression of 5hmC, with 5hmC scores ranging from 3-9. In some cases, staining was weak (1+) but present in the majority of cells. In contrast, expression of 5hmC was deficient in 93% (25/27) of HCC cases. The intensity and percentage of 5hmC expression in HCC were dramatically reduced compared to surrounding benign hepatocytes or cirrhotic nodules. No significant difference in 5hmC expression was seen between HCC tumor grades (Chi-Square test, p=0.19). 83% (5/6) cases of HA exhibited intact 5hmC expression, with most cases showing slightly reduced 5hmC expression compared to neighboring benign hepatocytes. Conclusions: Nearly all cases of HCC in our cohort were deficient for 5hmC expression, compared to intact 5hmC expression in normal/cirrhotic surrounding hepatocytes and HA cases. 5hmC could serve as an important diagnostic tool in the diagnosis of HCC, and suggests an underlying role for epigenetic dysfunction in liver tumorigenesis. 
Upregulated MiR-125, MiR-181d and MiR-221 Expression Levels Are Associated with Poor Prognosis in Glioblastoma Patients with Unmethylated MGMT Promoter
Background: Glioblastoma (GBM) is the most malignant primary brain tumor with a poor prognosis. Several microRNAs have recently been identifi ed as potential prognostic biomarkers in GBMs. However, the previous studies are performed on relatively small sample sizes, and some important prognostic factors such as IDH-1 status, TMZ treatment and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status are not completely included. Design: One hundred and fourteen patients with primary GBM who had received TMZ chemotherapy with concomitant radiotherapy and had adequate follow-up data were included in the study. We analyzed the expression levels of several prognosis-related miRNAs (miR-125, miR-181d, miR-221, miR-222 and miR-224) and their relationships with survival in GBM patients. The expression levels were determined by real-time quantitative RT-PCR. MGMT promoter methylation status was also examined by methylation-specifi c PCR (MSP). Results: Up-regulated expression of miR-125, miR-181d, miR-221 and miR-224 were noted in 13.2%, 5.3%, 12.3%, 32.5% and 78.9% GBMs. The expression levels of miRNAs were not signifi cantly different by MGMT promoter methylation status. MiR-125, miR-181d and miR-221 had prognostic impact on MGMT unmethylated (MSP-) GBMs. Upregulation of any of these three miRNAs was signifi cantly associated with shorter survival in MGMT MSP-GBMs (fi gure 1).
Their impact on survival remains statistically signifi cant in multivariate anlyses with adjustment of age, gender, KPS, extent of resection, bevacizumab treatment, IDH1 status and MGMT methylation status (table 1). Conclusions: MiR-125, miR-181d and miR-221 are useful in predicting poor prognosis in MGMT unmethylated GBMs.
Distinctive CA9 Expression Patterns in Clear Cell, Microcystic and Angiomatous Meningioma Variants
Rati Chkheidze, Charles L White, Kimmo Hatanpaa, Chunyu Cai. UT Southwestern Medical Center, Dallas, TX. Background: Carboxic anhydrase IX (CA9) is a hypoxia-induced protein overexpressed in many tumor types and associated with worse disease outcome. Expression of CA9 in meningiomas has been described as zonal, mutually exclusive to blood vessels, and associated with high grade histology. Clear cell, angiomatous, and microcyctic meningiomas are three uncommon variants that are all rich in blood vessels but with diverse clinical outcomes. Observation from isolated cases demonstrated unique CA9 expression patterns in these variants. In this study, we systematically compare the CA9 expression patterns of these three variants to conventional meningiomas. Design: We Searched UTSW neuropathology database from 2000 to 2015 and identifi ed meningiomas with prominent angiomatous (N=10), microcystic (n=7), or pure clear cell (n=6) morphologies. Immunostain for CA9 was performed on complete sections on all cases. The results were compared to those of 35 conventional atypical meningiomas. Results: In conventional meningiomas (meningotheloid, fi broblastic, transitional), CA9 staining is zonal, hypoxia restricted, and mutually exclusive to blood vessels. Strong expressions are typically seen in perinecrotic cells and areas with small cell change. All clear cell meningiomas showed complete or near complete absence of CA9 expression. Microcystic meningiomas, on the contrary, demonstrated uniform, diffuse CA9 positivity. Angiomatous meningiomas were more variable, most cases contained intermixed conventional or microcystic meningioma areas. Nine were negative for CA9 in the confl uent vascular areas, one case showed diffuse positive staining similar to the micorcystic variant. Conclusions: Our data show that CA9 staining demonstrates an all versus none expression pattern in microcystic and clear cell meningiomas, respectively, as opposed to a zonal, hypoxia restricted pattern in conventional meningiomas. The diffuse staining patterns irrespective of hypoxia gradient suggest a constitutive activation or inactivation of hypoxia pathway proteins in these meningioma variants. The distinctive staining patterns may aid in the diagnosis of equivocal cases. These data also point out potential pitfalls in using CA9 as a general poor prognosis marker in meningiomas.
CRX and FOXJ1 Immunohistochemistry Differentiates Papillary Tumors of the Pineal Region from Pineal Parenchymal Lesions
Shannon Coy, Sonika Dahiya, Alexandre Vasiljevic, Sandro Santagata. Brigham and Women's Hospital, Boston, MA; Washington University School of Medicine, St. Louis, MO; Wertheimer Hospital, Lyon, France. Background: Papillary tumors of the pineal region (PTPR) are rare neuro-epithelial tumors found in the pineal region. Despite their anatomic association with the pineal region and frequent histologic similarity to lesions of the pineal gland parenchyma; PTPR have transcriptional and ultrastructural features consistent with an origin in the sub-commissural organ. CRX immunohistochemistry (IHC) has been shown to specifi cally label benign pineal gland and pineal parenchymal lesions, but does not label ependymal cells. FOXJ1 is a master regulator of motile ciliogenesis which is highly expressed in cells of ependymal origin, but is not known to be expressed in pineal gland. We hypothesized that PTPR would show differential expression of CRX and FOXJ1 compared to pineal parenchymal lesions. Design: We reviewed a diverse series of pineal region tumors including pineal parenchymal lesions and PTPR, as well as ependymomas, meningiomas, pilocytic astrocytomas, and medulloblastomas. All cases were stained using IHC for CRX. A subset of cases was stained with FOXJ1. Results: CRX IHC strongly and diffusely labels the nuclei of benign pineal gland (9/9, 100%) and all lesions of pineal parenchymal origin, including pineal cysts (4/4, 100%), pineocytomas (9/10, 90%), pleomorphic pineocytomas (2/2, 100%), PPTIDs (14/14, 100%), and pineoblastomas (5/5, 100%). FOXJ1 IHC was negative (0% of cells) in pineal gland and lesions of pineal parenchymal origin. CRX is negative in 75% of PTPR cases (9/12), with only rare expression (<5% of cells) in the remaining cases. FOXJ1 is diffusely and strongly positive in 100% of cases of PTPR examined. CRX is negative in all cases of ependymoma (0/44, 0%), meningioma (0/143, 0%), and pilocytic astrocytoma (0/23, 0%). A subset of medulloblastoma cases (22/49, 45%) showed at least focal staining with CRX. Conclusions: IHC for CRX and FOXJ1 robustly differentiates PTPR from benign pineal gland and lesions of pineal parenchymal origin. Our fi ndings support the hypothesis that PTPR arise in the sub-commissural organ rather than the pineal gland. Given the marked histologic overlap of lesions in this anatomic region, IHC for CRX and FOXJ1 will likely be broadly applicable for evaluation of lesions of the pineal region.
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Loss of H3K27me3 Is a Poor Prognostic Factor for Meningioma Areli K Cuevas-Ocampo, David Raleigh, Ashley Wu, Bryan Tomlin, Joshua Menke, Gerald Reis, Arie Perry, Tarik Tihan, Melike Pekmezci. University of California in San Francisco, San Francisco, CA; Memorial Regional Hospital, Hollywood, FL. Background: Although genetic alterations in meningiomas are relatively wellcharacterized, our understanding of meningioma epigenetics is incomplete. Trimethylation of lysine 27 at histone 3 (H3K27me3) is associated with either poor or favorable prognosis in various tumors. The aim of this study is to determine whether H3K27me3 loss has prognostic implications in meningiomas, which is currently unknown. Design: We retrospectively identifi ed patients treated for meningioma from 1997 to 2014 with available tissue and clinical information. Immunohistochemical stains for H3K27me3 were scored as loss (staining in <50% cells), partial loss (50-95%) or retained (>95%). We analyzed the association of H3K27me3 status with local recurrence-free survival (LRFS) and overall survival (OS) by the Kaplan-Meier method and log-rank tests. Relationships between LRFS or OS and age, sex, grade, setting (primary or recurrent), multiplicity, extent of resection and H3K27me3 status were analyzed by multivariate regression. P ≤0.05 was considered statistically signifi cant. Results: 230 meningiomas from 218 patients with a median age of 60 years (range 19-87) were included. Median follow up was 4.2 (1-15) years. H3K27me3 loss was associated with grade III and recurrent meningiomas (Table 1) , but not with age, sex, location, or MIB1 index. On univariate analyses, H3K27me3 loss was associated with reduced LRFS and OS, and partial loss was associated with reduced OS. On multivariate analysis, grade III histology and subtotal resection, but not H3K27me3 loss, were associated with reduced LRFS. H3K27me3 loss, grade III histology, recurrent meningiomas and age were associated with impaired OS on multivariate analysis. Background: Primary histiocytoid/signet ring cell carcinoma(SRCC) of the eyelid is a rare, aggressive neoplasm favored to arise from the eccrine sweat glands. Histologically, this tumor shows diffuse infiltration of the eyelid by single cells with histiocytoid appearance resembling SRCC of the gastrointestinal tract and breast. In SRCC of gastric and breast origin, E-cadherin dysregulation plays a central role in pathogenesis. Specifically, E-cadherin/B-catenin complex is required to maintain the integrity of epithelial cell-cell contact and keeps Wnt/B-catenin signals in check. Additionally, during tumor progression, epithelial-mesenchymal transition(EMT) alters E-cadherin expression with elevated SRC. As mechanisms contributing to tumorigenesis of histiocytoid/SRCC of the eyelid remain unknown, we analyze protein expression in key genes in E-cadherin related pathways. Design: Three cases of primary histiocytoid/SRCC of the eyelid and orbit were treated at MD Anderson Cancer Center with surgical resection from 1990-2016. Clinicopathologic findings were evaluated and confirmed the primary site of origin. Immunohistochemical studies for expression of E-cadherin, B-catenin, c-Myc, cyclin D1, SRC, p53 were performed. Results: We report 3 eyelid tumors that histologically proved to be histiocytoid/SRCC in 3 male patients aged 55-81 years. Clinically, infiltrative, firm cutaneous masses encircling the periocular area and orbit are noted. One of the patients has history of contralateral eyelid involvement, status post radiotherapy. Microscopically, cords of atypical histiocytoid cells arising from eccrine dermal ducts are identified infiltrating skeletal muscle and orbit. Perineural invasion is seen. Follow-up examination shows evidence of metastatic disease to the neck in one of the patients. Immunohistochemically, E-cadherin expression is completely lost in 2 of 3 cases which is accompanied by heterogeneous/loss of B-catenin expression. Focal cyclin D1 is noted in all 3 cases. Conversely, one case retains E-cadherin with associated increased SRC compared to the other 2 tumors with weak SRC expression. Alterations in p53 and c-Myc expression are not identified. Conclusions: Histologic findings continue to link histocytoid/SRCC of the eyelid with origin in the eccrine glands; however, metastasis to this region must be excluded. We believe this tumor is biologically similar to primary histiocytoid/SRCC of breast with alterations in expression of the E-cadherin/B-catenin complex. EMT may also contribute to pathogenesis and requires further evaluation. Background: MCL is a B-cell lymphoproliferative disorder (B-LPD) that involves the orbit and ocular adnexa with a more aggressive course than other small B-LPDs. MCL demonstrates the presence of t(11;14)(q13;q32) with overexpression of cyclin D1. Diagnosis depends upon IHC demonstration of cyclin D1 protein expression and translocation detection in cyclin-D1 negative cases. Variant morphologies, including blastoid and pleomorphic MCL, make the diagnosis challenging. Proper diagnosis of MCL is crucial to patient care as patients are often treated aggressively, including with stem cell transplantation. SOX11, a member of the SOX family of transcription factors, plays a role in neural development. It has been detected in the majority of MCLs, including those with variant morphology and is negative in almost all other B-LPDs. Design: We reviewed lymphoma cases involving the orbit and ocular adnexa diagnosed during 2007-16. MCL cases were reviewed for morphology, clinical parameters including age, gender, clinical features, and systemic involvement. IHC/flow cytometry results were documented. SOX11 IHC was performed on formalin-fixed paraffin-embedded tissue in MCL cases using an automated immunostainer (Bond-Max, Leica Microsystems Inc.) and monoclonal anti-SOX11 antibody Cell Marque clone MRQ-58 (1:100 dilution). Specimens with >10% nuclear staining were considered positive.
Results: Of the 8 MCL cases identified, there were 7 orbital and 1 conjunctival tumors. There were 6 males and 2 females; age range of 55-77 (mean: 67.5) years. Bilateral disease was not seen; 5 right-sided and 3 left-sided cases. Orbital/adnexal MCL as first presenting symptom comprised 75% of cases. Prior systemic involvement was seen in 2 cases with relapse. The most frequent symptoms were pain, epiphora and diplopia; most frequent clinical signs were eyelid mass, conjunctival swelling and proptosis. All patients received rituximab chemotherapy and 3 cases are in complete remission. On IHC/ flow cytometry, all cases expressed B-cell marker CD20 and cyclin D1. CD5 was positive in 7/8 cases. Kappa and lambda light chain restriction was seen in 2 and 6 cases respectively. Strong and diffuse SOX11 staining (> 75% cells) was seen in all 8 cases.
Conclusions:
The orbit and adnexal region is involved by MCL in elderly patients with a male predominance and can be the first presentation site. SOX11 IHC is a reliable tool to identify MCLs in small biopsies in conjunction with cyclin D1, including cases with variant immunophenotypes and/or morphology.
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GlioSeq Targeted NGS Panel Provides Accurate Genetic Profiling of Pediatric CNS Tumors for Clinical Care Soufiane El Hallani, Ronald L Hamilton, Craig M Horbinski, Ian F Pollack, Abigail Wald, Yuri Nikiforov, Somak Roy, Marina N Nikiforova. University of Pittsburgh Medical Centre, Pittsburgh, PA; Northwestern Memorial Hospital, Chicago, IL. Background: Genomic analyses of pediatric brain tumors have discovered a number of specific molecular alterations and signatures that, when combined with histology, can re-classify these tumors (PMID: 26304884) and improve patient management. The aim of this study was to evaluate the clinical utility of testing pediatric CNS tumors with our GlioSeq NGS panel, and assess whether the emerging research-based molecular classifications can be reproduced in the clinical setting. Design: We reviewed pediatric and young adult CNS tumors tested in our institution with GlioSeq panel. GlioSeq is a targeted NGS panel designed to detect point mutations/ indels in 30 CNS tumors related genes, copy number variations (CNVs) in 24 genes, and 14 types of gene fusions using minimal nucleic acid material from clinical FFPE specimens (PMID: 26681766). Information on demographics, histopathological diagnosis, and reported genetic alterations were included in the study. Based on detected genetic alterations, we were able to categorize 28 out of 30 high-grade gliomas (93%) into K27, G34, IDH, RTK, or Mesenchymal subgroups of the newly proposed molecular classification of pediatric high grade gliomas. Conclusions: In the majority of cases, molecular profiling of pediatric CNS tumors by GlioSeq enabled the detection of genetic alterations that enhanced diagnostic accuracy. It also correctly assigned the correct molecular subgroup in the vast majority of pediatric high-grade gliomas, providing valuable information for precision diagnosis and patient management.
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Expresion of HER2 in Ocular Surface Squamous Neoplasia Evangelina Esposito, Pablo Zoroquiain, Ana B Toledo Dias, Miguel N Burnier. McGill University, Montreal, QC, Canada. Background: C-erbB-2/neu (HER2) is an oncogene associated with poor prognosis, metastatic potential and aggressive biological behavior in several tumors including breast, stomach and others. HER2 amplification is also associated with the responders to anti-HER2 treatment. Ocular surface squamous neoplasia (OSSN) is a spectrum of neoplastic lesions of the conjunctiva ranging from papilloma to invasive squamous carcinoma (SCC). Moreover, SCC is the most frequent malignant neoplasia of the conjunctiva and 33% of them will metastasize. The aim of this study is to evaluate HER2 expression in the progression of OSSN and as a potential therapeutical target. Design: Ninety eight OSSN lesions including 17 papillomas (P), 27 conjunctival intraepithelial neoplasia (CIN) I, 19 CIN II, 13 CIN III and 11 SCC were evaluated. Eleven conjunctivas from eye bank eyes (NHE) were also included in the analysis. Immunohistochemistry was performed to analyze HER2 (clone 29D8) expression. HER2 expression was graded as follows: Complete membrane staining in more than 10% of malignant cells (3+); week to moderate complete staining in more than 10% of malignant cells (2+); no or fewer than 10% cells staining (0 to 1+) respectively. Positive HER2 was considered when a score 2+ or 3+ was detected. Breast carcinoma with HER2 amplifi cation was used as positive control. Statistical analysis was performed using Fischer's-Exact Test. Results: HER2 positive expression was detected in 6% of P (100% score 2+), 11% of CIN I (100% score 2+), 32% of CIN II (100% score 2+), 30% of CIN III (100% score 2+), 29% of SCC (50% score 2+ and 50% score 3+ Background: Primary CNS lymphoma is an aggressive disease, accounting for up to 3% of primary brain tumors and is comprised mostly of B-cell lymphomas (BCL). Whereas immunodefi cient individuals are at increased risk, primary BCL (PBCL) is increasing in the immunocompetent, especially the elderly. Differential diagnosis of BCL, based on imaging and symptoms, is broad and includes gliomas, infection, and autoimmune disease. Given its frequent parenchymal location, CSF fl ow cytometry and cytology often yield false-negative results. We examined CSF cytokine levels in various CNS diseases in order to identify clinically useful profi les distinguishing BCL from clinical mimics.
Design: CSF levels (pg/ml) of 42 cytokines were measured using a bead based ELISA in the following samples: 4 PBCL, 2 systemic BCL (SBCL), 3 malignant gliomas (T), 12 CNS infections (I), 7 autoimmune diseases (A), 4 multiple sclerosis (MS), 3 controls (C). Agglomerative hierarchical clustering (AHC) with heatmap was performed. Mann-Whitney test for signifi cance was used to compare groups. Receiver operator characteristic (ROC) curve was used to determine the utility of analytes as tests. Results: AHC depicts three major clusters in which all PBCL, SBCL, and autoimmune/ demyelinating diseases form a discrete class.
The heatmap demonstrated the following class properties: elevated IL1b, IL2, IL3, IL4, IL5, TNFβ, IL12p70; lower levels of IFNγ, MIP1a, IL1Ra, sCD40L. This pattern directly contrasts expression seen in the infection and tumor classes. PDGF-AA can discriminate lymphoma (PBCL/SBCL) from autoimmune disease (p=0.009 by MannWhitney; AUC=0.853 by ROC) with higher levels in lymphoma.
Conclusions:
We have shown a robust characterization of CNS diseases based on cytokine expression, which holds clinical potential. When adjunct testing (cytology and fl ow cytometry) is non-informative, BCL can be distinguished from its clinical mimics based on cytokine profi ling. PDGF-AA is a useful discriminating analyte, such that PDGF-AA is signifi cantly higher in lymphoma compared to other diseases within its cytokine-based class. Given the observed clustering, our study has also highlights that lymphoma and autoimmune/demyelinating diseases may share similar, pathogenic properties related to disease genesis.
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The Role of Histopathologic Subtype in the Setting of Hippocampal Sclerosis-Associated Mesial Temporal Lobe Epilepsy Jordan M Gales, Richard A Prayson. Cleveland Clinic Lerner College of Medicine, Cleveland, OH; Cleveland Clinic, Cleveland, OH. Background: Hippocampal sclerosis (HS) and focal cortical dysplasia are among the most common fi ndings in those undergoing surgery for refractory mesial temporal lobe epilepsy (MTLE). Existing data regarding differences among the most recent International League Against Epilepsy (ILAE) HS subtypes remains limited. Focal cortical dysplasia of the adjacent temporal lobe is increasingly reported to coexist with HS. The relationship between the two remains unclear. This study sought to examine the clinical signifi cance of HS subtype and coexistent focal cortical dysplasia among those undergoing epilepsy surgery for MTLE. Design: 307 resections for temporal lobe epilepsy with ipsilateral HS were reviewed (mean age ± SD, 37 ± 15 years, 56% women). HS and coexistent lesions of focal cortical dysplasia were classifi ed according to ILAE consensus guidelines. Medical records were reviewed for data on seizure recurrence and seizure burden during clinical follow-up (mean duration ± SD, 5±4 years). Results: Cases of typical HS (ILAE type I) predominated [ILAE type Ia: 41%, Ib: 47%, II: 11%, III: 0.7%]. The HS subtypes shared similar demographic and etiologic characteristics, as well as associated pathology and post-operative seizure outcomes at 2 and 5 years following surgery. Individuals with type Ib HS were more likely to remain seizure free at long term follow-up when compared to other subtypes, and they reported a later age of seizure onset. Two hundred-forty three cases (79%) demonstrated focal cortical dysplasia within the adjacent temporal lobe. Its presence was associated with a signifi cantly decreased risk of seizure recurrence (p=.02), especially during the early post-operative-period. When present, focal cortical dysplasia was predominantly Type I (98%). The effect of coexistent focal cortical dysplasia upon overall epilepsy surgery outcomes at 2 years, 5 years, and long term follow-up was not signifi cant, when measured by the Engel epilepsy surgery outcome scale. Conclusions: HS subtype does not appear to affect epilepsy surgery outcomes, despite some clinical differences between the subgroups. Focal cortical dysplasia is often observed in association with HS in MTLE; the clinical implications of this remain uncertain. However, the fi ndings of this study suggest its presence is associated with better post-operative outcomes when compared to those with isolated HS-associated MTLE. New Hypothesis in the Pathogenesis of Diabetic Retinopathy Alireza Ghaffarieh. Indiana University, Indianapolis, IN. Background: DIABETIC RETINOPATHY, A retinal vascular disorder that occurs as a complication of diabetes mellitus (DM), is a leading cause of blindness in the United States. Although brain and retina are embryologically similar, and both vascular beds are exposed to similar concentrations of blood glucose, the extensive microvascular pathology develops only in the retinal capillaries , not in the cerebral capillaries. The initial step in the delivery of glucose to the retina and brain is its transport across the blood-retinal barrier (BRB) or the blood-brain barrier (BBB) by the major glucose transporter, GLUT-1. Glucose infl ux in retina exceeded that of the cortex by about threefold for the nondiabetic and the glucose levels in the diabetic retina are fourfold to sixfold greater than the nondiabetic retina. The investigators concluded that the expression of GLUT-1 in the microvasculature does not account for the glucose accumulation in the retina in diabetes. G6Pase is found mainly in the liver and the kidney, plays a key role in the homeostatic regulation .We hypothesized that the increase in retinal glucose levels during diabetes is from increased entry into retina at the RPE-choroid interface through glucose-6-phosphatase (G6P)-mediated activity of retinal pigment epithelium cells. Design: For immunostaining, the sections eye from patients with advanced stage diabetes and normal were deparaffi nized, rehydrated and anti-glucose-6-phosphatase antibody has been applied . We also treated diabetic mice with intravitreal injection of glucose-6-phosphatase inhibitor. Results: For the fi rst time, We have detected the glucose-6-phosphatase enzyme activity in the human retinal pigment epithelium. After blocking this enzyme in the diabetic mice model ,the severity of diabetic retinopathy was decreased.
Conclusions:
In Diabetes, the large amount of glucose enters the retina via the retinal pigment epithelium and these estimates are consistent with the presence of appreciable amounts of Glucose-6-Phosphatase. Blocking the glucose-6-phosphatase could be one of the new modalities of prevention and treatment for diabetic retinopathy.
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Determining IDH Status in Gliomas Using IDH1 R132H Antibody and Polymerase Chain Reaction Dibson D Gondim, Melissa AH Gener, Liang Cheng, Eyas M Hattab. Indiana University, Indianapolis, IN; University of Louisville, Louisville, KY; Children's Mercy Hospital, Kansas City, MO. Background: Determination of the mutation status of the IDH (isocitrate dehydrogenase) gene in diffuse gliomas has not only become the standard of care, but is also now incorporated in the nomenclature of main entities of this group, beginning with the WHO 2016 Classifi cation of Tumors of the CNS. IDH mutation status has prognostic, therapeutic, and diagnostic relevance. Among the several methodologies available for studying IDH mutations, assessment by IHC (immunohistochemistry) has the advantage of being incorporated in the routine pathology workfl ow and has the potential of detecting ~90% percent of the mutations. The WHO 2016 publication suggests confi rmation of negative IHC results by another diagnostic modality in all grades II and III diffuse gliomas or in grade IV glial tumors if the patient is younger than 55 years. To evaluate the WHO guidelines, we compared the detection of IDH mutation by IHC and PCR. Design: Monoclonal antibody for IDH1 R132H (Dianova-clone H09) and IDH1/2 RGQ PCR Kit (Qiagen) were both used to determine IDH mutation status. We included 62 cases of both diffuse and circumscribed gliomas (31 males, 31 females). The tumors were comprised of 30 glioblastomas (GBM), 11 grade III diffuse gliomas (6 anaplastic astrocytomas, 2 oligodendroglioma, 3 oligoastrocytomas), 17 grade II diffuse gliomas (9 diffuse astrocytomas, 4 oligodendrogliomas, 4 oligoastrocytomas), 1 anaplastic pilocytic astrocytoma, 2 pilocytic astrocytomas, and 1 ganglioglioma. Results: Of the 62 cases, 12 had IDH mutation by IHC and 15 by PCR; 3 false-negative results by IHC were identifi ed. PCR detected IDH1 R132H (11 cases); IDH1 R132C (1 case); IDH2 R172, NOS (1 case); IDH1 R132, NOS (1 case); and IDH2 R172K (1 case). R132H antibody had high specifi city (100%) and sensitivity (80%) to detect IDH mutations. More importantly, the positive predictive value was 100%. The three false-negative cases were two anaplastic astrocytomas (patients were 38 and 35 years of ages) and one diffuse astrocytoma (33 years of age). IHC did not detected IDH1 R132C and IDH2 R172 mutations, as expected. The antibody detected 12/13 IDH1 R132H mutations. Among the IDH-wildtype diffuse gliomas, GBMs had a highest proportion of wild-type cases (93%). Conclusions: Evaluation of IDH mutation could be approached in a stepwise fashion. The high positive predictive value of IDH1 R132H IHC justifi es ordering it as the fi rst step of evaluation. Nonimmunoreactive cases could then be studied by PCR following recommendations of 2016 WHO.
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Utility of Somatostatin Receptor 2a Immunohistochemistry in the Clear Cell Tumor Differential of the Central Nervous System
Abigail L Goodman, Jose E Velazquez Vega, Stewart Neill, Matthew Schniederjan, Stephen Hunter, Cynthia Cohen, Daniel J Brat. Emory University Hospital, Atlanta, GA. Background: Histologically similar primary and metastatic clear cell tumors occasionally involve the central nervous system (CNS) and can be diffi cult to distinguish by morphology. This is especially true for tumors with clear, often vacuolated cytoplasm and a rich vascular network, including metastatic clear cell renal cell carcinoma (mCCRCC), hemangioblastoma, and microcystic and clear cell meningiomas. We evaluated an immunohistochemical panel that incorporates somatostatin receptor 2a (SSTR2a) for distinguishing entities within the differential of clear cell CNS tumors. Design: We performed a search in our institutional database for cases of mCCRCC, hemangioblastoma, and clear cell and microcystic meningiomas. An immunohistochemical panel that included SSTR2a (UMB1, Abcam, Cambridge, CA, 1:400, Leica), CA IX, Pax 8, and Inhibin was performed on all cases. Criteria for positivity were established for each marker and a consensus was achieved for positive and negative staining for each tumor and stain. Results: We included 62 cases: 18 mCCRCCs, 30 hemangioblastomas, 3 clear cell meningiomas and 11 microcystic meningiomas. SSTR2a was strong and diffusely positive in 12 of the 14 meningiomas, but was negative in all mCCRCC or hemangioblastomas (100% specifi city, 86% sensitivity in this study). CA IX labeled all mCCRCCs and hemangioblastomas strongly and diffusely but was also positive in 9 microcystic meningiomas and 1 clear cell meningioma. All cases of mCCRCC demonstrated strong nuclear positivity for Pax 8 in at least two-thirds of the cells; no immunoreactivity was observed in any other tumor type (100% sensitivity and specifi city). Inhibin had high sensitivity (87%) and specifi city (97%) for hemangioblastomas, although staining was frequently focal and weak. (100) 18 (100) 1 (6) Hemangioblastoma ( Conclusions: The histopathologic distinction of CNS clear cell neoplasms is greatly aided by the use of an immunohistochemical panel that includes SST2Ra, Pax8 and inhibin. SSTR2a immunoreactivity was highly sensitive and specifi c for clear cell meningioma variants, while Pax8 and inhibin were sensitive and specifi c for mCCRCC and hemangioblastoma, respectively. CA IX labeled all mCCRCCs and hemangioblastomas strongly and diffusely, however it was frequently positive in meningiomas.
Analysis of Immunobiologic Markers in Primary and Recurrent Glioblastoma
Wesley Hiser, Paul Kubilis, Duane Mitchell, Jesse L Kresak. University of Florida, Gainesville, FL. Background: Glioblastoma (GBM) remains an invariably fatal disease and tumor progression may be linked to immune evasion strategies. Immune system function and tumor suppression relies on the complex interplay between stimulatory and inhibitory signals present in the tumoral immune microenvironment. GBMs generate a varied immune response and understanding the immune microenvironment may lead to novel immunotherapy treatments modalities. The goal of this study was to evaluate the expression of immunologic markers of potential clinical signifi cance in primary versus recurrent GBMs and assess the relationship between these markers and molecular characteristics of GBMs. Design: Fifty cases of GBM (38 primary and 12 recurrent) were evaluated and analyzed with immunohistochemistry for multiple immunobiologic markers (CD3, CD8, FoxP3, CD68, CD163, PD1, PDL1, CTLA4, CD70). Included were four paired cases of primary and recurrent GBM. Immunoreactivity was analyzed using Aperio software. In order to avoid nonspecifi c background reactivity, analysis was limited to only tumor-rich regions. Additionally, the software was calibrated to only recognize strongly positive immunoreactivity. Degree of strong positive immunoreactivity within the tumor was compared to patient and tumor characteristics including age, gender, MGMT promoter methylation status, and ATRX, p53, and IDH1 mutation status. Results: Using odds ratios, no signifi cant difference was identifi ed in any immune marker between the primary and recurrent glioblastomas, nor was a signifi cant change in immunoreactivity identifi ed among age intervals. IDH1 mutated GBMs had statistically signifi cant decreased expression of CD163 and CD70 and a trend for decreased PD1, CTLA4, and Foxp3. ATRX-mutated GBMs exhibited statistically signifi cant increased CD3 immunoreactivity, while those with p53 mutations were found to have signifi cantly increased CTLA4 immunoreactivity. The odds of having strong CD8 and CD68 reactivity was signifi cantly less in MGMT methylated tumors. No trends were identifi ed amongst the paired specimens. Overall, the ratios of CD8, foxp3, and CTLA4 to CD3 and of CD168 to CD68 decreased between primary and recurrent tumors.
Conclusions:
GBMs with features associated with a better prognosis (IDH1 mutation) exhibited an immunophenotype consistent with anti-tumor effects. The findings also suggest that the immunobiologic markers have greater association with the molecular characteristics of the tumor than with primary/recurrent status or age.
CD163 and PD1-PDL1 Promote a Hostile Microenvironment for CD8 Lymphocytes and Predict Poorer Survival in Glioblastoma
Miguel A Idoate, Alvaro Lopez Janeiro, Arturo Lecumberri, Iñigo Arana, Ricardo DiezValle, Francisco Guillen, Luis Mejias. University of Navarra, Pamplona, Navarra, Spain. Background: The immune response against Glioblastomas (GB) depends on inhibitory and activating forces. Programmed death ligand 1 (PDL1), its corresponding T cell receptor (PD1) and M2 macrophages are postulated to be relevant inhibitory mechanisms. CD137 expression is a relevant lymphocyte activation marker. In addition, it is important to standardize and quantify the expression of these factors. Design: Seventy-six clinically and molecularly characterized primary GB were studied. Immunohistochemical study against CD8 (clone C8/144B), PD1 (clone NAT105), PDL1 (clones SP142 and 28.8), CD137 (clone BBK-2) and CD163 (clone MRQ-26, M2 macrophages) was obtained. We evaluated regions of interest in two ways: a semiquantitative assessment by three observers and a quantitative one using digital image analysis. Statistical analyses were performed using STATA (version 12.0). Results: PDL1 clone 28.8 was mostly membranous and present in 30% of GB. Clone SP142 was cytoplasmic and present in 47% of GB. Concordance between both clones was poor (Kappa=0.33, p<0.001). We found good correlation between semiquantitative and quantitative evaluations for CD163, CD8 and PDL1 (p<0.001). CD137 expression was extremely low (<1% in all specimens). No difference in overall survival (OS) between high and low grades of CD137 expression was found. Adjusted Cox model showed an association between CD163 (HR=1.04, p<0.05) and, surprisingly, CD8 (HR=1.06, p<0.05 ), with a poorer OS. Higher CD8 values were associated with higher M2 macrophage infiltration (R=0.46). High PD1 expression was associated with poorer OS (HR=2.79, p<0.001). Adjusted regression model showed no association between PDL1 expression and OS. Conclusions: PDL1 clone 28.8 is an adequate monoclonal antibody to determine PDL1 expression in GB. We propose the use of image analysis as a valid quantification approach. CD163 and PD1 immunohistochemical expression are associated with poorer prognosis in GB. We hypothesize that M2 macrophage (CD163) recruitment and PDL1 expression may be a defensive strategy upregulated by GB in response to tumor infiltrating lymphocytes. This is also coherent with the absence of CD137 immunostimulatory marker of CD8 lymphocytes.
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Expression of Sonic Hedgehog (SHH) Signaling Molecules in Retinoblastoma and Medulloblastoma
Nafiseh Janaki, Amad Awadallah, Mark Cohen, Marta E Couce. University Hospitals Cleveland Medical Center, Cleveland, OH. Background: Retinoblastoma is the most common intraocular malignancy in children. Recent findings demonstrate an intricate genetic and epigenetic complexity behind these tumors following in most cases RB1 inactivation. Better understanding of the pathways involved will likely help in the development of new therapeutic approaches for these patients. A recent study has demonstrated that SHH pathway activation in retinoblastoma is associated with advanced disease. SHH activation also underlies approximately one third of cases of medulloblastoma, a relatively common pediatric brain tumor. Pathological activation of SHH pathway is felt to be responsible for all desmoplastic medulloblastomas as well as some medulloblastomas with classic histology. Several antibodies to SHH signaling proteins are commercially available. Currently immunohistochemistry for Grb2-associated adaptor protein-1 (GAB1) is considered one of the best methods to infer SHH pathway activation in medulloblastomas. We examined the expression profile of different SHH signaling proteins in retinoblastoma and medulloblastoma cases. We correlated these findings with clinicopathological parameters in order to identify the optimal immunohistochemical paradigm for assessing SHH pathway activation in these tumors. Design: Tissue microarrays (TMA) were constructed from 11 retinoblastomas and 8 medulloblastomas, each containing duplicate tissue cores of 1 or 1.5 mm diameter sampled from the most representative areas of the donor blocks. Immunohistochemistry was performed using a BenchMark Ultra immunostainer (Ventana system). The following antibodies were used: SHH, GAB-1, GLI-1, GLI-2 and GLI-3. The results were considered positive if 10% or more of the tumor cells were positive. Semiquantitative evaluation of positive markers was also performed. Results: As expected, all desmoplastic medulloblastomas and some classic medulloblastomas were positive with anti-GAB1 antibodies, with a moderate to high level of immunoreactivy. These cases also demonstrated predominantly high immunoreaction with SHH antibodies. Nine retinoblastoma cases were positive for anti-SHH, six of which were strongly positive. None of these cases were immunoreactive with GAB-1. Conclusions: GAB-1 is the current surrogate marker of choice for SHH activity in medulloblastoma, although SHH immunostaining provides similarly reliable results. On the other hand, GAB-1 should not be considered a reliable marker with which to assess SHH-activation in retinoblastomas.
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Loss of Expression of SWI/SNF Chromatin Remodeling Complex Proteins in Sporadic Pituitary Adenomas
Upasana Joneja, Markku M Miettinen, Varun Kshettry, James J Evans, Mark T Curtis. Thomas Jefferson University Hospital, Philadelphia, PA; National Cancer Institute, Bethesda, MD.
Background:
Pituitary adenomas account for 15% of all intra-cranial tumors. While considered benign, a high number of pituitary adenomas cause significant morbidity. 5% of the pituitary adenomas are caused by germline mutations but only few genetic alterations have been described in sporadic pituitary adenomas suggesting epigenetic alterations may play a role. Chromatin remodeling proteins including the SWI/SNF complexes are involved in gene expression, and dysregulation of this system is known to cause a variety of tumors. In this study, we analyzed the expression of a number of SWI/SNF complex proteins in sporadic pituitary adenomas to determine if their loss of expression may play a role in the biology of these tumors. Design: Immunohistochemistry was performed on tissue microarrays of 154 pituitary adenomas to determine the expression of the SWI/SNF complex proteins INI-1, ARID1A, BRG1, and SMARCD3. Complete absence of staining was considered loss of expression. Additional markers associated with pituitary adenoma behavior including Ki-67, p53 and IGF-1R were analyzed as were the mRNA regulator protein-HuR, an indicator of DNA methylation status-5-hydroxymethylcytosine (5HMC), and tumor associated macrophage marker-CD163. The expression of all the SWI/SNF chromatin remodeling proteins was correlated with staining of the other selected markers and with tumor functionality, invasiveness and recurrence rate. Results: Complete loss of expression was identified in 19% of the sporadic pituitary adenomas (10% for BRG1, 5% for ARID1A, 3% for SMARCD3 and less than 1% for INI-1).Two cases showed concomitant loss of expression of ARID1A and BRG1 and two others showed concomitant loss of expression of BRG1 and SMARCD3. One case showed concomitant loss of BRG1, ARID1A and SMARCD3. No correlation was identified between loss of expression of SWI/SNF complex proteins and tumor functionality, invasiveness, recurrence or immunohistochemical staining for Ki67, p53, IGF-1R, HuR, 5-HMC, or CD163. Conclusions: SWI/SNF chromatin remodeling protein expression is lost in 19% of sporadic pituitary adenomas. Dysregulation of the remodeling complexes may play a role in the genesis or progression of pituitary adenomas, reversal of which may provide a future therapeutic strategy for these tumors. Background: The use of targeted mutation profiling (TMP) is becoming an integral part of personalized management of patients with malignant tumors. Detecting a tumor's underlying genetic alteration (GA) can provide valuable diagnostic and prognostic information, yet the clinical actionability of TMP in brain tumors is unclear. The purpose of this study is to investigate if the use of TMP leads to implementation of genomically guided therapy in patients with difficult to treat brain tumors at our academic institution. Design: Our pathology archive was queried for CNS tumors which had been evaluated by extended next generation sequencing (NGS) assays. A total of 40 such CNS tumors were identified; 21 of which were evaluated using our in-house clinically validated NGS assay on the Ion Torrent Personal Genome Machine with the AmpliSeq Cancer Hotspot Panel v2 (reporting 33 genes) and 19 cases had been referred for Foundation One (FO) testing (Foundation Medicine, Cambridge, MA). A retrospective chart review was performed to identify therapies implemented in these patients. Results: A total of 25 metastatic CNS tumors were analyzed by NGS (21 utilizing our in-house assay and 4 sequenced by FO) and 15 primary CNS tumors were analyzed by FO. The FO platform revealed a total of 81 GA (4.25 GA and 1.47 actionable GA per each tumor). The in-house NGS assay revealed a total of 22 GA (1.05 GA and 0.09 actionable GA per tumor). The most commonly detected GA were TERT, CDKN2, TP53, NF1, EGFR, FGR, PTEN, ATRX, and KRAS. 19 out of 41 cases (46%) harbored actionable GA. 3 of these patients received genomically-targeted therapy; one targeting AKT2 amplification in an anaplastic meningioma (FO) and 2 targeting EGFR in metastatic tumors (in-house assay). Conclusions: 46% (19/41) of the tumors analyzed harbored actionable GA, however, only 16.7% (3/19) of patients received targeted therapy. Barriers to implementing targeted therapy are multifactorial. FDA approved targeted therapies are often reserved as 2nd line treatment to be used as the data on the efficacy of these drugs in the CNS is limited. In addition, access to the medication can be a time-consuming hurdle. Addressing key factors that facilitate the use of NGS results in oncologic care could benefit patients with difficult to treat CNS tumors.
H3 K27M Mutation in Gangliogliomas Can Be Associated with Poor Prognosis
Bette Kleinschmidt-DeMasters, Andrew Donson, Nicholas Foreman, Kathleen Dorris. University of Colorado Anschutz Medical Campus, Aurora, CO; Children's Hospital Colorado, Aurora, CO. Background: Spinal cord and brainstem diffuse midline gliomas have been shown to have H3F3A (K27M) mutations, which are paralleled by presence of strong, diffuse nuclear immunoreactivity using a high fidelity immunohistochemistry (IHC) stain. Although a World Health Organization (WHO) grade of IV has been assigned to diffuse midline glioma, H3 K27M-mutant, it is becoming apparent that rarely low grade tumors, including several case reports of pilocytic astrocytoma and ganglioglioma (GG), may also show this mutation. In these examples, eventual tumor progression and demise was recorded. This suggests that the presence of mutation may portend adverse prognosis in any tumor type in which it occurs. Given our previous experience with midline GGs, both pediatric and adult, we re-interrogated all previously-published + new cases for H3 K27M by IHC. All had clinical followup and either BRAF V600E mutational or BRAF VE1 IHC testing. Design: Review of files generated 14 patients with midline GGs (11 F : 3 M), 7 of which succumbed to their GG, and 5 of which came to autopsy. Results: 2 patients with midline GGs (1 brainstem:1 spinal cord; 1/2 were metastatic) were found to be H3 K27M mutant; both died of disease. The other 5 patients with demise were negative for mutation; 3/5 were metastatic. 4 had BRAF mutation; 1/4 was metastatic. No case had both H3 K27M and BRAF V600E mutation. Neither mutant GG had unusual histological features. Conclusions: H3 K27M mutation in GGs may be associated with poor prognosis, but the latter is not invariably associated with mutation.
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Ultrastructural that were evaluated for metabolic disease by electron microscopic (EM) examination. Of these patients, 178 also underwent a muscle biopsy. Results: Of the 630 skin biopsies, 75 (12%) showed EM abnormalities and 34 (5%) specifically showed mitochondrial abnormalities including increased mitochondrial size (n=27), reduced or abnormal cristae (n=23), dense matrices (n=20), and increased mitochondrial number (n=8). Sixteen samples demonstrated other findings including lysosomal abnormalities (n=13), lipid accumulation (n=2) or glycogen accumulation (n=1). Of the 34 patients with mitochondrial abnormalities on skin biopsy, 20 also had muscle biopsies performed; nine of these showed abnormalities specifically suggestive of a mitochondrial abnormality including absent cytochrome oxidase staining (n=2), increased subsarcolemmal NADH, SDH, or cytochrome oxidase staining (n=1), or EM findings including large mitochondrial size (n=5), abnormal mitochondrial structure (n=5), and increased mitochondrial number (n=4). The most common presenting symptoms were intellectual disability (n=13), seizures (n=12), encephalopathy (n=9), and gastrointestinal disturbances (n=9). At last known follow-up, 12 patients had been given a definitive diagnosis of a mitochondrial disorder. Specific diagnoses include one patient each with Complex I deficiency, Complex III deficiency, Charcot-MarieTooth disease, pyruvate dehydrogenase deficiency, and Phelan-McDermid syndrome. Conclusions: There is a subset of patients for whom skin biopsy reveals mitochondrial abnormalities. Among these patients, 45% of muscle biopsies showed findings suggestive of a mitochondrial abnormality. A skin biopsy sometimes yields diagnostic clues suggestive of a mitochondrial cytopathy in cases with a negative muscle biopsy.
Aggressive Genetic Signature Correlates with Tumor Cell Proliferation in Supratentorial Ependymoma
Michael B Miller, Adrian Dubuc, Azra H Ligon, Keith L Ligon. Brigham and Women's Hospital, Boston, MA. Background: Ependymomas comprise a class of glial neoplasms in the central nervous system. The W.H.O. 2016 current diagnostic guidelines specify grade II Ependymoma and grade III Anaplastic Ependymoma, but distinction between these is somewhat subjective, and definitive association with behavior has not been established. However, certain genetic variants, including C11orf95-RELA fusion, CDKN2A loss, and 1q gain, have been reported as associated with poor outcomes. Major questions remain regarding the relationship between tumor genetics and histological features. Design: In an effort to identify histological and genomic features which might improve ependymoma classification, we reviewed the histologic features, including mitotic rate and proliferation index (by MIB-1 immunohistochemistry), and genomic aberrations identified by microarray hybridization studies across a cohort of 40 patients, ages 2 -70 years, who had a diagnosis of Ependymoma, Anaplastic Ependymoma, or Myxopapillary Ependymoma. Results: Loss of the tumor suppressor gene CDKN2A, previously found to be associated with aggressive behavior, was observed in 8 cases, each of which was supratentorial and demonstrated a proliferation index greater than 15% (mean 26.2%). The majority of cases with retained CDKN2A showed a proliferation index less than 15%, particularly among supratentorial ependymomas. Among the few supratentorial cases which showed a proliferation index greater than 15% but retained CDKN2A, the deleterious chromosome 1q gain was found. Conclusions: These findings suggest that a proliferation index of >15% may identify a subset of supratentorial ependymomas with an aggressive genetic signature, bearing either CDKN2A loss or chromosome 1q gain. Infratentorial ependymomas (including posterior fossa and spinal cord sites) retained CDKN2A and demonstrated a wide range of proliferation indices.
Unexpected Pathologic Findings in a Subset of Malformations of Cortical Development
Vera Paulson, Rebecca Folkerth, Sanda Alexandrescu. Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Background: Imaging in chronic epilepsy may be indeterminate for neoplasia. We encountered an 8-year-old female with intractable epilepsy and imaging consistent with focal cortical dysplasia (FCD). The left temporal lobe and hippocampus were resected and showed changes of FCD. However, the presence of increased cellularity, mild glioneuronal atypia, and a positive BRAF V600E immunostain were consistent with ganglioglioma. This index case prompted a retrospective review of consecutive epilepsy specimens resected at Boston Children's Hospital (BCH) from 2012 to 2016 to determine the incidence of neoplasia in such specimens. Design: We identified 121 patients with epileptic foci resections, and subsequently excluded from evaluation those with prior tumor diagnoses, tuberous sclerosis, hemimegalencephaly, inflammatory processes, strokes, encephaloceles, and prior brain surgery. Demographic and clinical data, resection location, magnetic resonance imaging (MRI), and histological and immunohistochemical results (including a low grade glioma panel in 9 cases) were reviewed. Results: Forty-five patients (19 male, 26 female) ranging in age from 7 months to 19 years old (median: 9 years) were identified. Their MRIs predominantly demonstrated malformations of cortical development, though the findings were indeterminate in 7 patients. There were 23 temporal lobe (13 with hippocampus), 18 frontal lobe, 3 parietal lobe, and 1 occipital lobe resection specimens. The specimens with non-neoplastic histology were classified according to the International League Against Epilepsy (ILAE) classification system as FCDIa (2), FCDIIa (17), FCDIIb (9), FCDIIIa (3), FCDIIId (1), mesial temporal sclerosis (4, 1 with polymicrogyria), and polymicrogyria (1). Three cases demonstrated non-specific changes only. Five cases demonstrated increased cellularity and cytologic atypia and were classified as ganglioglioma (3), low grade glioma (1), and atypical glial proliferation (1) following immunohistochemistry and molecular studies. BRAF V600E mutation was present in all three gangliogliomas. Conclusions: Our study shows that 8.9% of BCH patients undergoing epilepsy surgery, without MRI studies definitive for tumor, have low grade glial and glioneuronal neoplasms. Therefore, the presence of increased cellularity and cytologic atypia, beyond the typical secondary reactive changes present in the setting of epilepsy, should prompt ancillary molecular studies for a neoplasm.
Dutcher Bodies in Lacrimal Glands: Not Always a Reliable Feature in Distinguishing Malignant from Benign Lymphoid Infiltrates
Sabrina Racine Brzostek, Jeffrey Ahlstedt, Yanhua Wang. Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY. Background: Dutcher bodies are nuclear pseudoinclusions of eosinophilic PAS+ cytoplasmic nuclear invaginations that have been used as clues in distinguishing a benign lymphoid aggregate from malignancy, such as multiple myeloma, lymphoplasmacytic lymphoma, and MALT lymphoma. This study describes a case series of 14 lacrimal gland surgical pathology cases wherein no lymphoproliferative disorder was identified, yet populations of Dutcher body containing plasma cells were frequently identified. Design: Montefiore Medical Center's LIS was data-mined using the keyword lacrimal gland during 4/2014 -4/2016. Histology was reviewed, eliminating specimen lacking lacrimal glands. Clinical histories and IHC were reviewed for malignancy, presence of Dutcher bodies and IgG4 related disease. Additionally, 3 cases were selected to evaluate the Ig heavy chain profile of the plasma cells by IHC. Results: The LIS search resulted in identifying 25 cases. Malignancy (small B cell lymphoma, marginal zone lymphoma and extranodal marginal zone lymphoma) had been reported in 3 cases; 2 cases were excluded due to lack of lacrimal glands within the specimen. Of the remaining 20 cases, 14 were identified as containing Dutcher bodies in the context of chronic dacryoadenititis, chronic inflammation or benign hyperplasia. Ig heavy chain staining on 3 of the benign specimens revealed a mixed, but predominate IgA+, plasma cell population, when compared to a selected lymphoma with IgG+ plasma cells. B-cell rearrangement molecular testing on a Dutcher body-containing benign specimen also revealed polyclonality. IgG4 related disease had been evaluated in 7 of 14 benign Dutcher body cases, and found to be negative.
Conclusions:
Historically Dutcher bodies have been associated with malignancy, with only 2 prior studies identifying the feature in benign conditions: chronic synovitis and ocular adnexal benign lymphoid hyperplasia. The findings in this study support the underappreciated association of Dutcher bodies in benign reactive conditions, such as dacryoadentitis. Therefore, caution must be exercised in utilizing Dutcher bodies in a low grade orbital lymphoma work up, especially in the lacrimal gland.
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Is It Worthy to Reclassify Already Diagnosed Oligoastrocytomas in the Setting of the New WHO Criteria? Irma Ramos-Oliver, Laura Abraira, Jordi Temprana-Salvador, Carolina Montecino, Jessica Camacho, Cristina Auger, Francisco Martínez-Ricarte, Santiago Background: IgG4-related disease is an immune-mediated fibro-inflammatory condition characterized by tumefactive swelling of involved organs, dense lymphoplasmacytic infiltration, markedly increased IgG4+/IgG+ plasma cell ratio, storiform-type fibrosis, and often but not always elevated serum IgG4 concentrations. Orbital structures are among the most common anatomic sites for IgG4-related disease. We studied the prevalence of IgG4-related disease in relation to age, sex and orbital sites in a total of 54 chronic orbital inflammatory lesions identified from our institution. Design: 54 patients (32 female, 22 male, 5 to 92 yo, 87% over 40 yo) with chronic orbital inflammatory lesions, including 6 lacrimal glands, 18 intraorbital soft tissue/extraocular muscle (EOM) masses, and 30 lacrimal ducts/sacs, were included in our studies. IgG and IgG4 immunostains were performed. IgG+ plasma cells and IgG4+ plasma cells were counted in three high power fields in comparable areas of inflammation and the average IgG4+/IgG+ plasma cell ratio was determined. Lesions with an average IgG4+/ IgG+ plasma cell ratio of 30% or greater were placed in the IgG4-related disease group. The histopathologic features, and when available, serum IgG4 levels, were documented. Results: Orbital lesions from five patients (three male, two female, 54 to 88 yo,) satisfied the criteria of IgG4+/IgG+ plasma cell ratio of 30% or greater and showed variable degree of fibrosis associated with lymphoplasmacytic infiltration. These include two lacrimal glands, two intraorbital soft tissue/EOM masses, and one lacrimal sac. Four lesions revealed IgG4+/IgG+ plasma cell ratio over 60%. IgG4 serum levels were available in three of the five patients, two with elevated serum IgG4 and one with normal serum IgG4. All three patients responded to steroid therapy. One possible case with IgG4+/IgG+ plasma cell ratio of 20% was observed in a 46 yo male with an intraorbital soft tissue/EOM mass. Interestingly, markedly increased IgG4+/IgG+ plasma cell ratio was also observed in an intraorbital mass from a 41 yo female with granulomatosis with polyangiitis with positive antineutrophil cytoplasmic antibodies. Conclusions: IgG4-related orbital disease occurred in late middle-aged to elderly patients. More men than women were affected by IgG4-related orbital disease. IgG4-related orbital disease was most prevalent in lacrimal glands, followed by intraorbital soft tissue/EOM masses, and least common in lacrimal ducts/sacs. Caution should be practiced in diagnosing IgG4-related orbital disease in patients with granulomatosis with polyangiitis.
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Clinicopathological Features of C11orf95-RELA Positive Ependymomas in a Series of Adult and Young Patients with Long FollowUp Sabrina Rossi, Luisa Toffolatti, Riccardo Signori, Elena Boscato, Lucia Zanatta, Anna G Volpato, Laura Valori, Matilde Cacciatore, Antonella Peciarolo, Stefano Ascani, Cristina Pizzato, Paolo Grotto, Elisabetta Marton, Caterina Giannini, Pierluigi Longatti. Treviso General Hospital, Treviso, Italy; S. Maria Hospital, Terni, Italy; Mayo Clinic, Rochester, MN. Background: RELA fusion-positive (RELA+) ependymoma, a new WHO 2016 entity, is driven by C11orf95-RELA fusion leading to the activation of NF-kB pathway and potentially sensitizing the tumor to targeted therapies. RELA+ ependymomas account for 1/3 of all pediatric supratentorial ependymomas (SE) and have a dismal prognosis compared to SE lacking RELA fusion (RELA-). C11orf95-RELA is associated with clear cell morphology with branching capillaries and L1CAM expression. Little is known regarding RELA+ SE occurring in adults. We studied a cohort of 6 adult and 3 young patients (1 infant, 2 adolescents), exploring the clinicopathological correlates of C11orf95-RELA fusion Design: Formalin fixed paraffin embedded SE were screened for type 1 and 2 C11orf95-RELA transcripts by real-time RT PCR, followed by sequencing, and for L1CAM expression by immunohistochemistry. CGH analysis was carried out in 2 RELA+SE with suitable DNA (1 adult, 1 adolescent). A set of 45 non supratentorial ependymomas (nonSE) and 5 subependymomas (subE) were also tested for L1CAM. Results: C11orf95-RELA transcript (type 2) was identified in 2/6 adult (33%) and 2/3 young (75%) SE. L1CAM was exclusively expressed in RELA+ SE and was negative in the additional 45 nonSE and 5 subE. Overall, RELA+ and RELA-SE were similar in terms of sex, grade and behavior. In adult SE, clear cells with branching capillaries were seen only in the 2 RELA+SE; instead of the 3 young SE, 1 RELA+ and 1 RELA-SE displayed this phenotype. Notably, in 1 RELA+ SE, morphology changed over time acquiring an unusually infiltrative growth pattern. Chromotripsis of chr 11 or abnormalities affecting 11q12-q13 region involved in the translocation were found in the 2 RELA+ SE analyzed by CGH. Clinicopathological correlations are summarized below
Age ( Conclusions: In our series, enriched for adult cases and with long follow-up, C11orf95-RELA fusion was not uniformly associated with dismal prognosis. L1CAM may be a surrogate for molecular analysis.
Ki 67 Labeling Index Is Superior to IMP3 in Prediction of Meningioma Recurrence; a Pilot Study
Mohamed M Shareef, Doha E Fayed, Rania E Wasfy, Karima I Marey. Tanta University, School of Medicine, Tanta, Egypt; Kafer El Sheikh General Hospital, Kafer El Sheikh, Egypt. Background: Recurrence is a major clinical issue of meningiomas. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is a marker of uncontrolled cell proliferation and aggressiveness in many tumors. However, little is known about its relation to meningioma behavior especially recurrence. Ki-67 is a well-known excellent marker for determining the growth fraction and hence biological aggressiveness of tumors. Many authorities advocate this marker for prediction of meningioma recurrence yet with many controversies and different cut-off values. This study aimed to compare the predictive value of IMP3 and Ki 67 in meningioma recurrence. Design: Forty surgical meningioma specimens were recruited with their clinicopathologic and follow up data. The cases were composed of 28/40 cases (70%) of grade I, 9/40 cases (22.5%) of grade II and 3/40 cases (7.5%) of grade III. The de novo cases were 31/40 (77.5%) and the recurrent cases were 9/40 (22.5%) . The specimens were stained immunohistochemically for IMP3 and Ki 67. Positive IMP3 expression (unequivocal cytoplasmic and/or nuclear staining in more than 5 % of tumor cells) and Ki 67 labeling index (with 4 % cut-off value) were analyzed in relation to the relevant data (age, gender, site, size, recurrence and survival). Results: Positivity for IMP3 was observed in 32/40 (80%) of all specimens, in 25/31 (80.6%) of de novo specimens and in 7/9 (77.8%) of recurrent cases. Significant relations were found between IMP3 and patient gender (p=.037) and tumor size (p=.039). IMP3 showed high sensitivity for predicting recurrence (90%), low specificity (26.92%), Positive Predictive Value (PPV) of 32.14%, Negative Predictive Value (NPV) of 87.5% and accuracy of 44.44 with overall unacceptable performance as a predictive marker for recurrence in ROC curve (AUC=.588, p=.417). The Ki-67 labeling index was high in 20/40 (50%) of all specimens, in 16/31 (51.6%) of the de novo specimens and in 4/9 (44.4%) of the recurrent specimens. Significant relations were found between Ki 67 labeling index and tumor grade (p=.001) and IMP3 expression (p=.002). Ki 67 labeling index showed sensitivity of prediction of recurrence of 60%, specificity of 53.85%, PPV of 33.33%, NPV of 77.78% and accuracy of 55.56 with overall acceptable performance (AUC=.742, p=.026). Conclusions: Ki 67 labeling index (with 4 % cut-off value) has a good discriminating power in predicting meningioma recurrence, superior to IMP3 which showed an unacceptable performance as a predictive marker of recurrence.
Interestingly, 60% tumors of oligoastrocytic group could be categorized as pure oligodendroglial or astrocytic. IDH mutation analysis assisted in diagnosing primary (wildtype; n=12; 48%) and secondary (mutant; n=4;16%) glioblastomas (GBM). Remainder of the GBM cases were of GBM, NOS category. Additionally, eight cases of GBM with oligodendroglial component (GBM-O, WHO, 2007) were re-classified as GBM, NOS (n=4), GBM, IDH mutant (n=1), and GBM, IDH wildtype (n=3). Conclusions: Our study emphasized the utility of molecular analysis in the classification of the glial neoplasms as pure oligodendroglial or astrocytic in nature, validating and reiterating the new WHO classification. 60% tumors of oligoastrocytic group could be categorized as pure oligodendroglial or astrocytic. GBM and GBM-O categories were further classified as primary and secondary based on their IDH status. The new classification ramifies further relevant genomic analyses, which have important therapeutic and prognostic implications. Further studies with a larger cohort of patients with clinical follow-up information are warranted to substantiate the current findings.
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A Recurrent Kinase Domain Mutation p.D463H in PRKCA Defines Chordoid Glioma of the Third Ventricle David Solomon, Benjamin Goode, Michael D Hyun, Nancy M Joseph, Jessica Van Ziffle, Nicholas Butowski, Daniel J Brat, Bette Kleinschmidt-DeMasters, Fausto Rodriguez, David N Louis, William Yong, Beatriz Lopes, Marc Rosenblum, Tarik Tihan, Andrew Bollen, Arie Perry. University of California, San Francisco, San Francisco, CA; Emory University, Atlanta, GA; University of Colorado, Denver, CO; Johns Hopkins University, Baltimore, MD; Massachusetts General Hospital, Boston, MA; University of California, Los Angeles, Los Angeles, CA; University of Virginia, Charlottesville, VA; Memorial Sloan Kettering Cancer Center, New York, NY. Background: Chordoid glioma is a rare brain tumor variant thought to arise from ependymal cells of the lamina terminalis along the anterior wall of the third ventricle. The molecular pathogenesis and optimal treatment strategy for this tumor are unknown. Design: Targeted next-generation sequencing of 480 cancer-associated genes was performed on 10 chordoid gliomas and matched normal tissue. Site-directed mutagenesis was performed on a human PRKCA cDNA. Wild-type or p.D463H mutant PRKCA were expressed in immortalized human astrocytes by lentiviral infection, and cellular phenotypes were assessed including signaling pathway activation and tumorigenic capacity. Results: A somatic p.D463H missense mutation in PRKCA was identified in all of the ten chordoid gliomas as the solitary and defining genetic alteration. PRKCA, which encodes protein kinase C alpha, has not been previously identified as a recurrently mutated gene in any human tumor type, although an SLC44A1-PRKCA gene fusion was recently identified in papillary glioneuronal tumors. The p.D463H mutation replaces a critical aspartic acid residue within the active site of the encoded kinase domain that functions as the proton acceptor during ATP hydrolysis. How this recurrent mutation causes chordoid glioma is still under investigation. Our initial functional experiments using lentiviral transduction of wild-type and p.D463H mutant PRKCA into immortalized human astrocytes have not revealed increased phosphorylation of known phosphotargets of protein kinase C (e.g. MARCKS and c-Raf), potentially suggesting a novel gain-of-function caused by this recurrent hotspot mutation.
Conclusions: These studies define a novel genetic biomarker in chordoid glioma of the third ventricle and suggest a promising therapeutic target for this rare brain tumor. Background: Arising from melanocytes in the choroid, ciliary body, or iris, uveal melanoma (UM) is the most common primary intraocular malignancy in adults. A substantial percentage of UM have an aggressive clinical course and exhibit a propensity to hematogenously metastasize to the liver, while others are indolent and can be treated more conservatively. A few panels of genetic markers exist that can provide prognostic information and stratify tumors based on the chance of metastasis. Monosomy 3 has been classically demonstrated to be an adverse prognostic factor, likely due to loss of one copy of the tumor suppressor gene BAP1. However, other biological mechanisms can inactivate one copy of BAP1, including copy-neutral loss of heterozygosity (LOH). Here, we compare DNA microarray analysis, fluorescence in-situ hybridization (FISH), and next generation sequencing (NGS) in a cohort of UM cases. Design: From July 2014 to June 2016, enucleation or excision specimens of melanoma involving the orbit from five patients at a single institution were collected. Three of the specimens were clinically diagnosed as primary UM, while two were clinically diagnosed as local invasion of cutaneous melanoma originating from the eyelid. On all five specimens, a genome-wide SNP-based microarray analysis was performed (Oncoscan), as well as a targeted NGS assay of 397 cancer-related genes. In addition, monosomy 3 analysis by FISH was performed on the cases of UM. Results: In one case of UM, FISH showed the normal two copies of chromosome 3, while Oncoscan identified a copy-neutral LOH at 3p21, the area of the BAP1 tumor suppressor gene. For the other two cases of UM, the results were concordant: One case was positive for monosomy 3 and one case was negative for chromosome 3 abnormalities by both modalities. NGS identified GNAQ or GNA11 mutations in all cases of UM and a BAP1 mutation in the case that was positive by both FISH and Oncoscan. The two cases of cutaneous melanoma involving the eye were biologically distinct, with Oncoscan revealing no alterations of 3p21 and NGS showing no GNAQ or GNA11 mutations, but a BRAF V600E mutation in one case. Conclusions: DNA microarray technology enables a high resolution view of copy number abnormalities and, for SNP-based arrays, includes the ability to identify LOH. Thus, it appears to be more sensitive for detecting alterations that affect the tumor suppressor gene BAP1 in UM. In addition, comparing NGS and Oncoscan results of UM and cutaneous melanoma cases serve to highlight their distinct biology.
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MUC4 Is Expressed in Meningioma with High Sensitivity for the Microcystic Variant
Toyohiro Tada, Hisashi Tateyama, Megumi Yoshida, Takashi Matsumoto. Toyokawa City Hospital, Toyokawa, Japan; Kasugai City Hospital, Kasugai, Japan. Background: MUC4 (Mucin 4, a transmembranous glycoprotein) has recently been identified as a sensitive amd relatively specific marker for sclerosing epithelioid fibrosarcoma/low-grade fibromyxoid sarcoma among mesenchymal tumors. However, anything on MUC4 immunoreactivity in neoplasms of central nervous system is not known yet. We investigated MUC4 expression in meningiomas using immunohistochemistry (IHC). Design: Formalin-fixed and paraffin-embedded 67 cases of WHO grade I meningioma of central nervous system were retrieved from our pathology files. Hematoxylin-Eosin stained slides of all of them were reviewed to confirm the diagnosis and histological subtype. IHC studies for MUC4, EMA, CD34, STAT-6, and MIB-1 were performed in each subtype. We analyzed and compared IHC findings among the subtypes for MUC4 and EMA. Results: All the tumors were negative to CD34 and STAT-6. The 67 meningiomas were subtyped (26 meningothelial, 6 transitional, 15 fibrous. 15 microcystic, 3 angiomatous and 2 psammomatous). Results of IHC for MUC4 and EMA are summarized in Table  1 . Except for fibrous variant, the overall sensitivity of MUC4 and EMA to others were same (47/52, 90%). Although the MUC4-positivity for fibrous variant (33%) was low, in microcystic variant showed 100% positivity and the staining score was very high. Five of 67 cases were completely negative for EMA, but instead they were positive for MUC4. (9) 10 ( 15) 32 (48) 42 (63) 29 (43) Conclusions: MUC4 is preferentially expressed in meningiomas. It is noteworthy that MUC4 is a more sensitive and stronger marker for the microcystic meningioma than EMA. In cases negative for EMA, MUC4 IHC can be alternatively useful for diagnosis of meningioma.
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Is Non-HIV Related DLBCL in the Brain Always Primary? Hammad Tashkandi, Marta E Couce, Mark Cohen. University Hospitals Cleveland Medical Center, Cleveland, OH. Background: In the absence of HIV infection, diffuse large B-cell lymphomas involving brain parenchyma are believed to represent primary neoplasms without the requirement for systemic staging. Conversely, CNS lesions in patients with extraneural diffuse large B-cell lymphoma are usually ascribed to infectious, autoimmune, and/or therapy related complications. Design: A search of our pathology archives from 2000-2016 identified 54 parenchymal CNS lymphomas. After clinical and pathological review, patients were divided into two groups: De novo (primary) CNS lymphoma (group 1) and CNS lymphoma preceded by systemic lymphoma (group 2). Additional clinical information obtained included age, gender, race, systemic therapy prior to CNS involvement, HIV status, lymphoma subtype, and time between diagnosis of systemic and CNS lymphoma. Results: 33 male and 21 female patients ranged in age from 26 to 90 years; 51 of 54 were white. Two cases of CNS and systemic lymphoma were diagnosed synchronously, while seven cases developed metachronously 5 to 9 years following diagnosis of systemic lymphoma. All but 2 cases were negative for HIV the time of diagnosis. Conclusions: Our retrospective analysis of CNS lymphoma cases showed that intraparenchymal CNS lymphoma arose in the context of systemic lymphoma in 9 of 54 patients (17%) with all but 2 of these developing in patients without HIV infection. The possibility of synchronous or metachronous CNS involvement by lymphoma should be considered in the differential diagnosis of these lesions. Background: Extraordinary interventional procedures are often required to treat pediatric patients with severe, life-threatening cardiopulmonary defects. One underreported complication is embolization of foreign material. We previously reported a series of pediatric postmortem cases demonstrating clinically unsuspected foreign body embolization to the central nervous system (CNS) following invasive diagnostic and therapeutic cardiovascular procedures. In this updated study, we examine the prevalence of embolic foreign material in an expanded cohort and compare this prevalence to a control group. We also investigate a possible source of the embolic material. Design: Autopsy brain slides for all infants and children with a history of cardiac catheterization, cardiopulmonary bypass, and/or ECMO collected over the course of 5 years at a pediatric tertiary care institution were reviewed for light-microscopic evidence of embolic foreign material. The prevalence of foreign material in this group was compared to a control autopsy group of pediatric patients with no history of cardiovascular procedures. To determine one possible source of embolic foreign material, we reenacted a cutting catheterization procedure on the laboratory bench and evaluated the resultant particulate matter. Results: Of the 24 patients in the study group (13F, 11M; ages 6 days to 20 years, median 9 months), eight (33.3%) had foreign material in the CNS in one or more blocks (sampling ranged from 4-19 blocks/case, median 12.5). In contrast, none of the control patients (7F, 3M; ages 2 weeks to 19 years, median 8 years) had foreign material in the CNS (sampling ranged from 6-19 blocks/case, median 12.5). In all instances, this material was associated with cellular inflammatory reaction and infarcts. The particulate matter produced during the reenacted catheterization procedure was similar histologically to embolic foreign material identified in a subset of the patients' CNS. Conclusions: Children dying with heart disease and a history of instrumentation have an appreciable risk of foreign material embolization to the CNS. This material can be vaso-occlusive, resulting in infarction. Cardiac catheters are one potential source of this material. To determine whether SC might be amenable to immune checkpoint blockade, we assessed the expression of PD-L1 and correlated this with the density of associated tumor infiltrating lymphocytes in a series of SCs. Design: Twelve SCs, including 10 primary ocular sebaceous carcinomas (POSC), 1 paired metastatic ocular sebaceous carcinoma (MOSC) and 1 primary extra-ocular SC (PEOSC) from a total of 11 patients (6 men and 5 women) were subjected to immunohistochemical studies with antibodies for PD-L1 (22C3 clone). PD-L1 positivity was scored as % tumor cells positive. The density of associated tumor infiltrating lymphocytes (TILS) was scored using a sliding scale (1+, 2+, 3+). Results: Overall, 4/12 (33%) SCs exhibited positivity for PD-L1. In POSC, 3 of 10 lesions exhibited PD-L1 positivity (range: 3-10% of tumor cells). One paired MOSC from one patient exhibited a similar degree of positivity as the primary lesion (3% of tumor cells). A single PEOSC studied was negative for PD-L1. The tumor associated lymphohistiocytic infiltrate exhibited variable PD-L1 positivity in all cases. No correlation was observed between the density of the TILS and tumor cell expression of PD-L1.
Conclusions:
The identification of tumor cell reactivity for PD-L1 in 33% of SCs implicates immune checkpoint blockade as a potentially effective therapeutic intervention to minimize the morbidity and mortality of a subset of patients with this aggressive ocular malignancy. Design: A 25 y/o male with a 5 year history of a primary CNS IMT presented with a second recurrence causing obstructive hydrocephalus. The tumor initially arose in the posterior fossa, first recurred in the right parietal lobe 19 months after resection and then presented with a second recurrence, an enhancing extra-axial 3cm mass associated with the fourth ventricle and superior aqueduct. The patient was chemotherapy and radiotherapy naïve. We performed FISH testing, a cytogenomic microarray and a Sarcoma Fusion Panel (SFP) 26 in the most recent surgical specimen. Results: All surgical specimens were morphologically identical and comprised of bland myofibroblastic-type spindle cells arranged in a loosely myxoid background with an abundant lymphoplasmacytic infiltrate. Immunohistochemistry for SMA was strongly and diffusely positive within tumor cells. Abundant entrapped islands of brain parenchyma were highlighted with GFAP immunostain. ALK immunohistochemistry was negative and FISH did not detect ALK and RET rearrangements. The SFP 26 identified a TFG-ROS1 gene fusion. Conclusions: Imperfect correlations between IHC and ALK mutation status in IMTs warrant additional molecular testing to elucidate ALK, ROS1, PDGFRB, NTRK3, and RET alterations that have diagnostic and therapeutic implications given the increasing development of targeted tyrosine kinase inhibitors. The frequency of ROS1 rearrangements in ALK-negative IMTs has not been fully determined yet but is currently estimated to be present in 10% of IMTs. To date, 13 ROS1 rearranged IMTs have been described and 4 of these had TFG as a fusion partner; none occurred within the CNS. We describe the first ALK-negative CNS IMT with a potentially actionable TFG-ROS1 fusion, providing a possible therapeutic alternative for targeted therapy in this aggressively behaving IMT. Jose E Velazquez Vega, Sameer H Halani, Safoora Yousefi, Fatemeh Amrollahi, Chad A Holder, Laila M Poisson, Brent Griffith, Jennifer Eschbacher, Michael Nalisnik, Jeffrey J Olson, Lee AD Cooper, Daniel J Brat. Emory University School of Medicine, Atlanta, GA; Henry Ford Hospital, Detroit, MI; St Joseph's Hospital, Phoenix, AZ. Background: Diffuse gliomas are now classified by their molecular genetic alterations, with oligodendrogliomas defined by IDH-mutations and 1p/19q whole-arm codeletions. Grading schemes derived from the pre-IDH era may not be optimal within the current classification and markers of progression have not been fully defined. Using molecular-genetic and clinical data, along with digitized pathology and MRI features, we investigated markers associated with disease progression in oligodendrogliomas. Design: IDH-mutant, 1p/19q co-deleted gliomas, grades II and III, were selected from The Cancer Genome Atlas (TCGA). Pre-operative MRIs were reviewed for contrast enhancement (CE) and radiographic necrosis (rNEC). Scanned H&E slides were evaluated for cell density (low-intermediate-high) by histologic review and by a nearest-neighbor algorithm of digitized images. Necrosis (+/-), vascular changes [none-hypertrophy-microvascular proliferation (MVP)], and Ki67 values by IHC were noted. Statistical analysis was performed to identify relationships between features of progression (MRI, histology, Ki-67 indices), genetic alterations and clinical outcomes. Results: Fifty-five tumors had MRIs for review, of which 35 were CE+ and 20 were CE-; 10 CE+ had rNec. CE+ and rNec were associated with higher WHO histological grade (p<0.001), increased Ki-67 expression (p=0.003), shorter overall survival (p=0.04), and were enriched for NOTCH1 mutations. Gain of chromosomes 7p and 11p, and loss of 15q were copy number alterations (CNAs) exclusively seen in CE+. Among 141 tumors with scanned diagnostic slides, we found that high cell density, defined by histologic review (p=0.0835) and by computation approaches (p=0.0775) correlated with a shorter overall survival and were enriched with ZBTB20 mutations (p=0.0559). NOTCH1 mutations were associated with necrosis (p=0.0467). Among 89 tumors with Ki67 data, those with with indices > 15% by IHC were associated with a shorter survival (p=0.0153) and enriched for PI3K subunit mutations (p= 0.068). Conclusions: Based on our multimodal analysis of molecular, histologic, radiologic and clinical data, we found features of progression in oligodendroglioma, including CE+, high cell density and Ki67 indices and necrosis were associated with specific genetic alterations, including NOTCH1 mutations. Biomarkers of progression will be useful in the stratification of risk for oligodendrogliomas in the molecular era.
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Markers of Progression in Oligodendroglioma
(AMP). Resulting libraries were quantitated and sequenced on the Illumina MiSeq System. Bioinformatics analyses were performed using custom scripts. Copy number alteration was detected using a read depth approach after consolidation of single molecule derived reads. INI1 immunohistochemistry was performed. RNA ISH for SMARCB1 was performed. Results: Five tumors were of hybrid histology, and all five were syndromic. Reduced copy number for NF2 was identified in 33% of vestibular schwannomas and 18% of nonvestibular schwannomas. There was no significant difference in reduced copy number of NF2 between sporadic and syndromic forms. BRAF V600E and NF1 mutations were not identified in any case. For most INI1 mosaics (figure 1), there was no molecular event explaining the partial loss of INI1 IHC.
Conclusions:
This study confirms the association of hybrid histology with syndromic schwannomas. NF1 mutations did not explain hybrid histology. We did not find BRAF V600E mutations in this series. INI1 mosaic pattern was not explained by reduced copy number or mutation of SMARCB1 as this was found in only a small number of the cases. RNA levels of SMACB1 were evaluated and will be subsequently reported. These results suggest that loss of INI1 expression could be the result of epigenetic alterations.
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SSTR2 Is Highly Expressed by Meningiomas: A Novel Diagnostic and Potential Therapeutic Target
Angela Wu, Andrew M Bellizzi. University of Iowa, Iowa City, IA. Background: Somatostatin, an inhibitory peptide with anti-secretory/proliferative effects, signals through somatostatin receptors (SSTRs). Somatostatin analogues (SAs) octreotide and lanreotide have greatest affinity for SSTR2, making it the most clinically relevant subtype. High-level SSTR2 expression in neuroendocrine (NE) tumors is the basis of somatostatin receptor imaging (SRI), SA therapy, and, very recently, peptide receptor radionuclide therapy (PRRT). Meningiomas were serendipitously found to express SSTRs as early as 1986, and the 1st report of SRI included 2 meningiomas. Current meningioma markers (e.g., EMA, PR) are insensitive, especially in higher-grade lesions, and non-specific. Given recent availability of a reliable monoclonal antibody, we investigated SSTR2 expression in a large cohort of meningiomas and diagnostic mimics. Design: Tissue microarrays were constructed from 177 meningiomas of various types; 19 solitary fibrous tumors/hemangiopericytomas (SFT/HPCs); 10 gliosarcomas; and 91, 27, and 10 consecutive carcinomas, melanomas, and sarcomas metastatic to brain. SSTR2 immunohistochemistry (clone UMB-1) was scored for extent (%) and intensity (0-3+) and an H-score (extent*intensity) calculated. Results: SSTR2 was expressed by 95% of meningiomas, including 97% G1, 95% G2, and 86% G3 tumors. Expression was diffuse, strong (i.e., H-score 200-300), even in higher-grade tumors. SSTR2 was expressed by only 1/19 SFT/HPCs, 1/10 gliosarcomas, 5/88 non-NE carcinomas, and not by any melanomas or sarcomas. SSTR2 was expressed by 2/3 NE carcinomas. Detailed expression data are presented below. Conclusions: SSTR2 is sensitive and specific for meningioma, even among highergrade lesions. Given high-level expression, PRRT should be considered for recurrent tumors having failed standard therapy (i.e., surgery and radiation).
